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Abstract
Purpose: The purpose of our study was to determine whether the amounts of circulating DNA (cDNA) could discriminate
between NSCLC patients and healthy individuals and assess its value as a prognostic marker of this disease.
Methods: We conducted a study of 309 individuals and the cDNA levels were assessed through real-time PCR methodology.
Results: We found increased cDNA levels in NSCLC patients compared to control individuals. We also found a decreased
overall survival time in patients presenting high cDNA levels, when compared to lower cDNA concentrations.
Conclusions: Quantification of cDNA may be a good tool for NSCLC detection with potential for clinical applicability.
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Introduction
Lung cancer is a worldwide problem. At the time of diagnosis,
50% of patients have advanced incurable disease. Different
chemotherapy combinations – with or without targeted therapies
– yield similar results despite the continuous efforts of clinicians [1].
Non-small cell lung cancer (NSCLC) accounts for about 80% of
lung cancers. No more than 10% of these can be treated with
surgery because of the lack of an early diagnosis or because of
a high frequency of metastasis at diagnosis [2]. The prognosis is
poor with only 10–15% of patients surviving 5 years after
diagnosis. This dismal prognosis is attributed to the lack of
efficient diagnostic methods for early detection and lack of
successful treatment for metastatic disease. Within the last decade,
rapid advances in molecular biology and radiology have provided
a rational basis for improving early detection and patients’
outcome. The aim for early detection is to identify lung cancer
at a stage early enough to be curable by surgery. Prognostic factors
predict survival independent of the treatment applied and can
classify patients as high or low risk. The most important prognostic
factor is stage according to the TNM system [3,4]. Other
prognostic factors include clinical aspects, as gender, age, weight
loss and cardiovascular disease, elevated lactate dehydrogenase
levels, FDG-PET scan and pathological aspects [5,6]. A major
hurdle in the attempts to improve the survival of these patients has
been the lack of a simple, non-invasive and effective test for early
prediction of therapeutic efficacy.
The finding that tumors are capable of shedding DNA into the
blood stream, which can be recovered from both serum and
plasma and used as surrogate source of tumor DNA, has opened
new areas in cancer diagnosis and prognosis [7]. A number of
studies have examined the mechanism behind origin and release of
free DNA in the circulation and its clinical implications for lung
cancer diagnosis, prognosis, and monitoring the effect of cytotoxic
therapies [7].
The presence of extracellular nucleic acids in the human
bloodstream was first described in 1948 by Mandel and Me ´tais [8].
In recent years, many studies identified genetic alterations in cell-
free circulating DNA (cDNA) from plasma or serum and tumor
DNA in many tumor types, including lung cancer [9].
Previous studies indicate that circulating nucleic acids in
peripheral blood are originated from tumors, through apoptosis,
necrosis or cell lysis of tumor cells [10,11]. The presence of tumor
DNA in blood is probably the result, in variable proportions, of
these different mechanisms, such as apoptosis, necrosis, cell lysis
and circulating tumor cells lysis, which produce DNA leakage or
excretion.
There are multiple potential uses for cDNA quantification in
cancer diagnosis and prognosis. It may represent a valuable source
of tumor DNA when the exact position of a suspected primary
lesion is not clearly defined, or when biopsies are not available
[12]. However, direct comparison of the available data is often
prevented by differences in the parameters analysed and by lack of
standardized methodology and analysis procedures. Any future
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purposes will depend on the reproducibility and reliability of
results, both of which require optimization and equivalent
procedures. For this study, we selected an assay designed for the
human telomerase reverse transcriptase (hTERT) genomic se-
quence that was consistently developed in a previous study [13].
The quantification of circulating DNA through a sophisticated
molecular method can be a useful diagnostic tool to differentiate
patients with tumors from healthy individuals and can identify
those with increased risk of cancer. There are several studies that
have valued the different concentration of free plasma DNA
among patients with lung tumors and healthy individuals, and
have used different data analysis methods and laboratory
procedures [14]. So far, the different methods utilized for sample
processing and storage, for the extraction and quantification of
plasma DNA and the choice of different target genes, have not
allowed the use of circulating DNA in the clinical practice [15].
The evaluation of the reproducibility of data obtained from other
groups is necessary for any eventual future application of this test.
For this purpose, we decided to apply a real-time PCR
methodology previously described [16], in order to confirm the
reproducibility of the results.
For this study, we selected an assay designed for the human
telomerase reverse transcriptase genomic sequence. Amplification
of hTERT was therefore used as a marker of the total amount of
DNA present in plasma samples. hTERT expression and
telomerase activity have already been reported as prognostic
factors in NSCLC patients [17,18]. However, this study is not
focused in the evaluation of hTERT expression as a tumor-
associated marker. Instead, our working hypothesis was based on
the use of a single copy gene, such as hTERT, as an indicator of the
global amount of circulating DNA. This methodology has already
been described by Sozzi and co-workers, and we processed our
samples using the same analytic and pre-analytic methods that
have been reported [16].
The present study was designed to analyze the efficacy of
circulating plasma DNA levels in discriminating lung cancer
patients from healthy individuals. Additionally, the utility of
circulating plasma DNA as a prognostic marker of survival and in
predicting response to therapy and disease progression was also
assessed.
Materials and Methods
Study Population
We evaluated 104 newly diagnosed and untreated patients with
non-small lung cancer (NSCLC) and 205 control individuals.
Since 2002, 104 consecutive Caucasian patients admitted to the
Portuguese Institute of Oncology of Porto (IPO-Porto), Portugal,
with cytological or histological confirmed NSCLC, have been
prospectively recruited to the study (median age 64.0 years; mean
age 63.2 years; sd 10.0).
Considering the patients gender, 20 (18.9%) were female and 86
(81.1%) male individuals and regarding smoking habits, 24
(23.1%) were non-smokers and 80 (76.9%) were smoker or
former-smoker individuals.
The control group consisted of 205 healthy individuals, 78
(38.0%) male and 127 (62.0%) female individuals, with a median
age of 50.0 years (mean age 47.3; standard deviation 11.6), without
clinical history of cancer, from the same geographic area as the
case group.
The patients were evaluated according to the TNM staging
system, and the assessment of tumour response to chemotherapy
was based on RECIST (Response Evaluation Criteria In Solid
Tumors). The first line chemotherapeutic protocol consisted of
platin-based doublet chemotherapy in combination with a third-
generation cytotoxic compound such as paclitaxel, gemcitabine or
docetaxel. The chemotherapeutic protocols were as follows:
cisplatin (80 mg/m2 on day 1) + paclitaxel (175 mg/m2 on day
1 every 3 weeks); cisplatin (100 mg/m2 on day 1) + gemcitabine
(1250 mg/m2 on days 1 and 8 every 3 weeks); carboplatin (AUC 6
on day 1) + paclitaxel (175 mg/m2 on day 1 every 3 weeks);
carboplatin (AUC 6 on day 1) + gemcitabine (1000 mg/m2 on
days 1 and 8 every 3 weeks).
The median follow-up time was 9 months (range 1–35 months).
Patients’ distribution according to the stage at the time of diagnosis
was 4 patients (3.8%) presenting localized disease (stages I and II)
and 100 (96.2%) with advanced disease (stages III and IV). From
all patients, the histological type distribution was as follows: 38
patients (36.6%) with epidermoid NSCLC, 54 (51.9%) with
NSCLC adenocarcinoma and 12 (11.5%) with other NSCLC
histological types.
The study was approved by the institute’s ethics committee.
Informed written consent was obtained from all the subjects,
according to Helsinki Declaration.
Sample Collection and DNA Isolation
A 5 ml sample of peripheral blood extracted from each patient
was collected in tubes containing EDTA and plasma was
immediately separated from the cellular fraction by centrifugation
at 2500 rpm for 10 min at 4uC. The resulting supernatant
(plasma) was frozen at –80uC. DNA was extracted from plasma
by using QIAamp DNA Mini kit (Qiagen, Hilden, Germany)
according to the manufacturer’s protocol. The purified DNA from
200 mL of plasma was eluted in a final volume of 70 mL of buffer
AE used for the elution and stored at –20uC.
DNA Quantification in Plasma
The quantification of cDNA was performed by a real-time
quantitative PCR method, based on a continuous monitoring of
fluorescence by an optical system [19]. The probe is labelled by
two fluorescent dyes, one serves as a reporter on 59 end (VIC dye;
Applied Biosystems, Foster City, CA). The emission spectrum of
the dye is quenched by a second fluorescent dye at the 39 end
(TAMRA; Applied Biosystems). Primers and probes were designed
previously by Sozzi and co-workers to amplify the gene of interest,
the hTERT single copy gene mapped on 5p15.33 [13]. The
primers and probe’s sequences were the following: primer forward,
59-GGC ACA CGT GGC TTT TCG- 39; primer reverse, 59-
GGT GAA CCT CGT AAG TTT ATG CAA- 39; probe, VIC5’-
TCA GGA CGT CGA GTG GAC ACG GTG-39 TAMRA.
Fluorogenic PCRs were carried out in a reaction volume of
25 mL in a 7300 ABIPRISM System (Applied Biosystems). Each
PCR reaction consisted of TaqMan Universal Mastermix (Applied
Biosystem), probe (7.5 mmol/L), primer forward (5 mmol/L),
primer reverse (5 mmol/L) and sterile water. DNA solution
(2.5 mL) was used in each real-time PCR reaction. Thermal
cycling was performed as previously described [13], and was
initiated with a first denaturation step of 50uC for 2 minutes and
then 95uC for 10 minutes followed by 50 cycles of denaturation at
95uC for 15 seconds and annealing and extension at 60uC for 1
minute. Each plate consisted of patient samples in duplicates and
triplicate blanks of water as negative control. The calibration curve
of each plate was calculated based on a dilution series of the
TaqMan Control Human Genomic DNA Standard (Applied
Biosystems) at 10 ng/ mL: 1, 0.1, 0.01, 0.001 and 0.0001 ng/mL.
All the data were analyzed using the 7300 System – SDS Software
(version 1.2.3) Sequence Detection Software (Applied Biosystems).
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in order to confirm the real-time PCR results. The protocol was
performed according to previously described [20]. Briefly, the
PCR reactions consisted of 30 rmol of each primer, 0.2 mM of
each dNTP, 1.5 mM MgCl2, 16Taq Buffer, and 1 U of Taq DNA
polymerase to a final volume of 50 ml. Primers used in the analysis
were CYF (59GTG AAG TTC ATT TCC AAT CCG C 39) and
CYR (59 GGG ACA TCA CCC TCA CCC TCA CTT AC 39).
Thirty five cycles were performed, consisting of an initial heating
at 95uC for 10 min to activate the enzyme, followed by 35 cycles of
denaturation at 94uC for 1 min, annealing at 55uC for 1 min and
extension at 72uC for 1 min, with a final extension step at 72uC for
2 min. PCR products (15 ml) were visualized by electrophoresis on
3% (v/v) agarose gels containing 0.5 mg/ml ethidium bromide.
This analysis was performed with 40 edged samples obtained with
real-time PCR methodology. Plasma samples of NSCLC patients
with the highest and lowest values of cDNA, 20 samples each,
were selected for this analysis. The band intensities from standard
PCR were compared with the real-time PCR results.
Statistical Analysis
Data analysis was performed using the computer software SPSS
for Windows (version 18.0) (SPSS Inc, Chicago, IL).
Linear amplification down to the last dilution was obtained in
each experiment (Pearson correlation coefficient, 0.999 to 0.995).
DNA concentrations between healthy controls and patients
were compared using the Mann-Whitney U- test. The Mann-
Whitney test was also used to compare DNA levels and patients’
clinical-pathological characteristics. P#0.05 was considered statis-
tically significant. For the diagnostic discrimination of DNA
concentrations between cancer patients and controls the area
under the curve of the receiver operating characteristic curve
(AUC–ROC) was assessed non-parametrically. A p-value of #0.05
was regarded as significant. An AUC-ROC equal to 1 denotes
perfect discrimination between patients with cancer and patients
without cancer, a value equal to 0.5 denotes the lack of
discrimination, and values in between indicate a degree of
discrimination between strong and poor.
Chi-square analysis was used to compare categorical variables
and a 5% level of significance was used in the analysis. The odds
ratio (OR) and its 95% confidence interval (CI) were calculated as
a measurement of the association between the amount of cDNA
and probability of lung cancer presence. Logistic regression
analysis was used to calculate the adjusted OR (aOR) and 95%
CI, with adjustment for age, gender and smoking status.
The probabilities of survival were calculated, and the means and
life tables were computed using the product-limit estimate of
Kaplan and Meier. The curves were examined by the Log rank
test, a statistical test for equality of survival distributions. Survival
duration was defined as the time between diagnosis and either
death or the last clinical evaluation of the patient. Clinical-
pathological data and cause of death was determined from the
patient’s medical records.
Results
Distributing the CDNA Values between Healthy and
NSCLC Patients
Our study was developed to investigate cell free circulating
DNA (cDNA) by a real time PCR quantitative approach,
performing all the technical procedures necessary for accurate
and reproducible results. The quantification of cDNA was
performed as previously described, by a real-time quantitative
PCR assay [13].
We confirmed the real-time PCR results with standard
amplification of cyclin D1 gene. We chose a different marker in
order to confirm the relative amount of cDNA in plasma samples
from NSCLC patients. Concordance of the amount of cDNA was
obtained for all tested samples (data not shown).
This quantitative assay shows a strong discrimination power and
a high sensitivity and specificity using the hTERT gene as a target
sequence for quantification of cDNA in plasma. For patients with
two or more samples collected after diagnosis and before
treatment, the mean cDNA concentration was calculated.
Plasma DNA was not associated with age and smoking history
in both case and control groups. However, considering the control
group, cDNA levels were increased in men individuals (Table 1).
There were no statistically significant differences in cDNA
concentrations between probands in different histological groups
and tumor stages (Table 2).
The mean cDNA plasma concentration in the control group
(mean rank 122.7 ng/ml), was statistically different from the mean
cDNA plasma concentration of the patient group (mean rank
270.0 ng/ml) (Mann-Whitney test, p,0.0001) (Figure 1).
Sensitivity and Specificity for Circulating Plasma DNA
Levels as a Diagnostic Marker
The ROC curve was made to evaluate the diagnostic power of
the circulating DNA concentration. The ROC analysis is
performed through the study of the function that links the
sensibility with 1-specificity. The subtended area by the ROC
curve (Figure 2) shows a synthetic index of the overall capacity of
the test in differentiating between healthy and ill individuals. The
closer the area gets to the unit, the greater its discriminating
ability. According to our data, the area under the ROC curve is
0.88 (95% CI, 0.84–0.92; p,0.0001). We found that lower cut-off
values increased the sensitivity of the assay but at the cost of
specificity and vice versa. Using the results of the ROC curve, an
analysis was made on the test performance with respect to the
different threshold values (Table 3). The results showed that, with
a threshold of 20 ng/mL, there is a probability of illness of 71%
when the test is positive (PPV). A DNA cut-off level of .20 ng/ml
differentiated between lung cancer patients and controls with
a specificity of 83% and sensitivity of 79%.
Table 1. Correlation between circulating plasma DNA levels
and demographic characteristics of the subjects.
Characteristics Mean rank of plasma DNA level (ng/ml)
Cases
(n=104) P* value
Controls
(n=205) P* value
Age (years)
,64 54.70 0.614 101.48 0.342
$64 51.68 69.33
Gender
Female 43.95 0.123 91.57 ,0.001
Male 55.72 121.62
Smoking history
No 50.33 0.688 58.72 0.217
Yes 53.15 66.79
*Mann-Whitney test.
doi:10.1371/journal.pone.0038559.t001
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An elevated concentration of plasma cDNA was associated with
a higher chance for the presence of NSCLC. Our results indicate
that high cDNA concentrations are more prevalent among cancer
cases, comparing to control individuals (Table 4). Data analysis
demonstrates that individuals with high cDNA concentrations
present an increased chance for the presence of NSCLC.
Keeping the cut-off value as the reference value equal to 6 ng/
mL, the relative risks of illness by DNA classes are shown in
Table 4. The risk of pathology increases as the DNA concentra-
tions increase: with concentrations between 6.0 and 20.0 ng/mL
the risk for illness is over 3 times higher, when compared with
cDNA concentrations lower than 6 ng/mL (OR, 3.33; 95% CI,
1.29–8.58; p=0.010); high concentrations greater than 20.0 ng/
mL are associated with a risk of illness of over 36 times higher
(OR, 36.71; 95% CI, 15.49–86.99; p,0.0001). For the cut-off
value of 20 ng/ml, logistic regression analysis adjusted by age,
gender and smoking status confirmed these associations (aOR,
12.69; 95% CI, 4.95–32.52; p,0.0001).
CDNA as a Prognostic Marker of NSCLC
We looked at correlation between pre-treatment circulating
plasma DNA levels and survival time in 73 NSCLC patients, who
received a first line chemotherapeutic protocol consisting of platin-
based doublet chemotherapy in combination with a third-gener-
ation cytotoxic compound such as paclitaxel, gemcitabine or
docetaxel and for which survival data was available. Survival
analysis was performed according to plasma DNA levels distribu-
tion using the Kaplan–Meier method and Cox-regression analysis.
The mean survival rates were statistically different according to
the patients’ cDNA concentrations, indicating that patients with
high cDNA levels presented a lower mean survival time than the
other patients (16.8 vs 22.4 months; Log Rank test, p=0.024).
Using a multivariate Cox regression model, we found a decreased
overall survival time in patients presenting high cDNA levels
(above 20.0 ng/ml), when compared lower cDNA concentrations,
with stage (P=0.171) as covariate (hazard ratio, HR=3.77; 95%
CI: 1.16–12.28; P=0.028) (Figure 3).
Discussion
Diagnostic assays based on blood sample analysis are becoming
an area of study with growing interest, mainly because of the
simplicity of sampling and the future potential of automation of
the technical methods for clinical applicability. The presence of
circulating tumor DNA in plasma of patients with lung cancer
arouse great interest since, with a simple blood test, a valid marker
could be set out for a possible screening, diagnosis, prognosis,
progression of disease and the monitoring of treatment response.
Unfortunately, the standardization of the test is difficult because of
the lack of a suitable standard test and the use of different
extraction and quantification methods [14,21].
Table 2. Correlation between circulating plasma DNA levels
and clinic-pathological parameters of NSCLC patients.
Characteristics
Mean rank of plasma DNA level
(ng/ml)
Cases (n=104) P* value
Histological type
Epidermoid 51.91 0.981
Non-Epidermoid 52.05
Tumor stage
I/II 64.25 0.427
III/IV 52.03
*Mann-Whitney test.
doi:10.1371/journal.pone.0038559.t002
Figure 1. Mean rank of cDNA plasma concentrations in pre-treatment NCLC patients and control individuals. *Mann-Whitney U-test.
doi:10.1371/journal.pone.0038559.g001
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in plasma/serum of cancer patients was first demonstrated in 1977
[22]. The possibility of recovering tumor-derived DNA from the
patient’s blood has provoked great expectation. This method offers
a non-invasive means to obtain tumor surrogate material, which
could represent a unique source for diagnostic and prognostic
applications. However, only recently cell free DNA is becoming an
issue of growing interest and its possible use as a marker for cancer
diagnosis or prognosis has been investigated. Recent studies
demonstrated higher cDNA levels in lung cancer patients
comparing to control individuals, however, the laboratorial
methods have not been consistently evaluated, namely the
procedures for DNA isolation and quantification [23]. Moreover,
there are some contradictory results regarding the analyses of the
clinical-pathological features, such as clinical staging and the
prognostic and predictive value of quantification of cell free DNA
and relapse-free evaluation that should be studied in more detail
[7,11,24]. A number of methods have been described to assess the
amount of DNA present in plasma, including competitive binding
radioimmunoassay, SYBER green, PicoGreen and others, but
most lack the sensitivity and specificity required.
Recent studies used real-time PCR methodology for cDNA
quantification [11,23,25,26]. The quantification of a single copy
gene seems a sensitive and adequate method for assessing cDNA
levels, and various markers have already been tested, namely,
amplification of hTERT [13,26], lactate dehydrogenase [11] and
beta-globin [25] genes. In the present work, we used real-time
PCR for DNA quantification, which can be regarded as the
standard method currently available [26].
In our study, we found no statistically significant differences in
cDNA concentrations between probands in different histological
groups and tumor stages. However, there is some controversy in
the relationship between DNA levels and the clinical-pathological
features [27]. Conflicting data have also been reported about
circulating DNA as a prognostic factor in lung cancer patients.
Some studies showed a correlation between an elevated plasma
DNA concentration and poor survival [11,25], whereas other
studies did not report such a relationship [16,26]. This might be
explained by differences in patient selection, covering both non-
small cell lung cancer (NSCLC) and small cell lung cancer (SCLC),
and both treated and untreated patients. Moreover, techniques for
sample collection and DNA quantification differed between these
studies. Thus, at present, the prognostic value of circulating DNA
for survival has not been established yet. Also, the relationship of
circulating DNA with age, gender, histology, stage and pulmonary
inflammatory conditions is not clear. Our results are in agreement
with the observations found in other studies, regarding the lack of
correlation between plasma DNA levels and clinical-pathological
parameters [11]. A correlation with age was reported in some
[1,13], but not in all studies [16,25]. Similarly, no correlation has
been established with histologic subtypes [16,28,29,30]. Disparity
also exists with regard to variables such as clinical staging. Some
studies report that plasma DNA was highest in patients with stage
IV disease [29], whereas in other studies there was no such
Figure 2. Receiver-operating characteristics (ROC) curve to calculate sensitivity and specificity of circulating plasma DNA as a tumor
marker of NSCLC.
doi:10.1371/journal.pone.0038559.g002
Table 3. Test performance.
Cut-off value
(ng/ml) Sensitivity Specificity PPV NPV
3 100.0 25.85 41.08 100.0
6 93.40 50.73 49.50 93.69
9 92.45 63.90 56.98 94.24
12 89.62 68.78 59.75 92.76
15 87.74 74.63 64.14 92.17
20 79.24 83.41 71.19 88.60
doi:10.1371/journal.pone.0038559.t003
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discrepancies in results across the studies might be due to technical
differences prevalent in various studies. These differences provide
an insight into the present status of circulating DNA research and
of the need for larger controlled studies with standardized
procedures.
We found increased levels of circulating DNA in NSCLC
patients compared to control individuals. Similar results were also
found in other studies, with higher DNA plasma concentrations
found in cancer patients when compared to healthy individuals
[13,16,26,31,32,33]. According to the majority of the quantitative
studies performed until the present time, cell free circulating DNA
is observed in healthy subjects at concentrations between 0 and
100 ng/ml of blood with an average of 30 ng/ml, whereas in
cancer patients the concentration in plasma or in serum varies
between 0 and 1000 ng/ml, with an average of 180 ng/ml [12].
However, these values constitute just a reference to evaluate cell
free DNA concentrations, as the percentage of circulating DNA
originated from tumor cells can vary from one cancer model to
another [12]. The plasma DNA concentrations observed in this
study were similar to the cell free DNA level averages described in
the literature [1,11,16,34].
The presence of free circulating DNA can be found in patients
with malignant pathologies, but also in healthy individuals and in
patients with non-malignant diseases, namely erythematic lupus,
rheumatoid arthritis, lung embolism, myocardium infarction,
Table 4. Frequency and odds ratio of plasma DNA concentrations among the control group and NSCLC patients.
cDNA levels (ng/ml) Controls (n=205) N (%) Patients (n=104) N (%) OR* 95% CI* P*
,6 104 (93.7) 7 (76.3) 1.00 Reference -
[6–20] 67 (81.7) 15 (18.3) 3.33 1.29–8.58 0.010
$20 34 (28.8) 84 (71.2) 36.71 15.49–86.99 ,0.0001
,20 171 (88.6) 22 (11.4) 1.00 Reference -
$20 34 (28.8) 84 (71.2) 19.20 10.58–34.87 ,0.0001
*For 20 ng/ml cut-off value, P,0.0001, OR=12.69 and 95% CI: 4.95–32.52, using logistic regression analysis adjusted by age, gender and smoking status.
doi:10.1371/journal.pone.0038559.t004
Figure 3. Cox regression analysis of overall survival according to cDNA levels, with tumor stage as covariate.
doi:10.1371/journal.pone.0038559.g003
Circulating DNA as Diagnostic Marker for NSCLC
PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e38559traumas or invasive therapeutics practices [35,36,37]. However,
DNA concentrations seem to be much higher in patients with
malignant pathologies [27,37]. There are various advanced
hypotheses about the release mechanisms of DNA in circulation.
For healthy individuals, it is presumed that circulating DNA
originates from the death of lymphocytes or other nucleated cells,
whereas for patients with neoplastic pathologies, there were several
hypothesis, namely lysis of tumor cells [12].
The purpose of our study was to confirm the results of the
previous researches about the free circulating DNA’s capacity of
differentiating healthy individuals from patients with NSCLC
cancer and to validate the method used for future clinical
application.
Increased plasma cDNA concentration was associated with
a higher probability of lung cancer presence. To our knowledge,
similar OR values were never reported previously for any biologic
marker and could be of substantial benefit in clinical practice. Our
study has confirmed the literature data, indicating that higher
DNA concentrations can be correlated with the condition of the
disease.
High plasma DNA levels were also associated with decreased
overall survival. Although there are conflicting results [31], some
studies also found a correlation between an elevated plasma DNA
concentration and poor survival [11,25,26,32].
A recent study has demonstrated that the levels of cell free DNA
present in cancer patients constitute a stable parameter over time
and its variations may be due to real clinical alterations in the
patient, as long as all the technical and methodological steps are
controlled [38]. Therefore, it becomes important to carefully
monitor the methods for blood sampling, plasma DNA isolation
and DNA quantification. Some quantification methods, such as
colorimetric kits, are not based on the amount of amplifiable DNA
but in the total amount of nucleic acids, which can include double-
stranded and single-stranded DNA and RNA.
A different approach has been described by Silva and co-
workers in colon cancer [39]. This study investigated the presence
of RNA from epithelial tumors in plasma from patients with
colorectal carcinomas and its correlation with tumor character-
istics and circulating tumor cells. Epithelial tumor RNA was
associated with advanced stages and circulating tumor cells.
The differences of the results observed in literature may also
reflect biological causes (histology, tumor origin, stage or tumor
size) or technical issues (blood processing, cell free DNA isolation
and quantification). There is insufficient data for the comparison
of all these parameters between different types of cancer, as it is
still unclear, whether all types of cancer can release altered cell free
DNA and at the same rate [12]. It has been demonstrated that
clearance of cell free DNA from the bloodstream seems to be
a rapid process, and one possible explanation is based on the cell
free DNA sensibility to plasma nucleases, such as DNAse1 [40].
Moreover, a study has demonstrated that, for a patient with
a tumor load of 100 g in size, up to 3.3% of the tumor DNA
entered the circulation every day [41]. In another study, mutations
in TP53 or KRAS2 were detected in whole blood at least one year
before diagnosis in 67% of patients, which indicates that tumor
DNA is released in blood before conventional diagnosis and
enhances the importance of this marker in cancer prevention [42].
Other tumor markers that play an important role in lung
carcinogenesis and are implicated in the treatment response of
NSCLC patients should also be evaluated, namely cyclin D1,
kRAS and EGFR (epidermal growth factor receptor). These
markers have been intensively studied in oncology and are directly
associated with lung cancer etiology. The analysis of these markers
should be performed in future works, in order to clarify its
correlation with lung cancer phenotype, tumor aggressiveness and
circulating DNA.
We think that the results are promising enough to encourage
further research in the area of circulating DNA as a tool for
monitoring therapeutic efficacy in lung cancer patients. Identifi-
cation of additional, more specific, and more sensitive plasma-
based biomarkers, which can be used in combination with
circulating DNA, may further improve the diagnostic power of
current imaging tools for indicating therapeutic efficacy.
Conclusions
This study demonstrates that higher levels of free circulating
DNA can be detected in patients with lung cancer compared to
healthy individuals by a quantitative PCR assay. We have shown
that the analytic procedure reported by Sozzi et al [13] is useful to
discriminate between healthy subjects and NSCLC patients. The
reproducibility of this method could represent a first step for its
future application in the clinical practice.
Although some concerns regarding the sample size and age of
case and control groups may be evaluated, this study suggests
a non-invasive diagnostic tool that can be further investigated in
future prospective studies for detection of lung cancer and
assessment of its potential applicability as a complementary
diagnostic and prognostic tool in clinical practice. We believe
that our results may help to improve discussion between
researchers in the field and that different methodological
approaches must be considered regarding the real meaning of
cDNA in lung cancer patients.
Levels of circulating DNA could also identify higher-risk
individuals for this disease screening and chemoprevention trials.
Furthermore, plasma DNA could also be used to detect cancer
specific molecular markers, such as mutations and amplifications,
and individualize and monitor drug treatment, namely resistance
to targeted therapies without the need for repeated tumor biopsies
in metastatic disease.
We found a significant decrease in the overall survival for higher
concentrations of cell free circulating DNA and a very significant
increase in the patients’ risk for the presence of lung cancer in
individuals with high cDNA levels. Cell free circulating DNA may
represent an important source of biomarkers at several steps of
carcinogenesis, including early detection of preneoplastic lesions
and monitoring of cancer. Moreover, levels of plasma DNA could
be tested as a potential intermediate biomarker of the efficacy of
intervention.
Large-scale prospective studies are necessary for population-
based studies and molecular epidemiologic studies, in order to
implement a clinical application in lung cancer detection,
diagnosis, prognosis and prediction of treatment response.
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